Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Should You Sell?

Posted by Teresa Graham on Oct 9th, 2026

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) gapped down before the market opened on Wednesday. The stock had previously closed at $40.00, but opened at $37.70. Zealand Pharma A/S shares last traded at $37.70, with a volume of 334 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ZLDPF shares. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Zacks Research raised Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, September 11th. Barclays lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Finally, Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Check Out Our Latest Stock Analysis on ZLDPF

Zealand Pharma A/S Stock Performance

The company has a current ratio of 13.98, a quick ratio of 13.98 and a debt-to-equity ratio of 0.02. The firm has a market cap of $2.69 billion, a PE ratio of 6.23 and a beta of 0.95. The stock’s 50 day moving average price is $46.05 and its 200 day moving average price is $46.28.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.